Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
## Vicarious Surgical at $0.05: A Penny Stock Reality Check with Heavy Filing Risk Signals
This marks the inaugural observation for RBOT (Vicarious Surgical Inc.) on Origin. At $0.05 per share as of October 9, 2026, the stock is trading in penny stock territory on the OTC market — a significant structural downgrade from its earlier Nasdaq listing. The 10-K filing signals are striking: the document contains 149 matches on the top risk factor categories, with a cumulative risk signal count exceeding 580 across eight flagged categories. This density of risk language in a single annual filing is a meaningful red flag, suggesting a company navigating an extraordinarily complex operational, financial, or regulatory environment. With zero earnings transcripts captured and 330 all-time AI queries on Origin, investor interest exists but formal management commentary is absent from the analytical record. The lack of transcript data makes it impossible at this stage to assess management tone, cash runway guidance, or any commercialization timeline for the company's robotic surgical platform. Vicarious Surgical had previously secured NASA partnership buzz and SPAC-era enthusiasm, but the $0.05 price reflects a harsh market reassessment of those narratives. Key things to watch next: any SEC filings indicating going concern language or reverse stock split proposals, cash and cash equivalents from the most recent balance sheet, and whether the company files a new 10-K or enters delinquency status. A management statement or investor update capturing in transcript form would substantially improve analytical visibility. The risk signal density alone warrants close monitoring.